Formulation and Evaluation of Oral Soft Jelly Containing Salbutamol Sulphate for the Treatment of Asthma

Abstract

Salbutamol sulphate oral soft jelly in asthma has been formulated and evaluated as the goal of the current investigation. A person with asthma has inflamed, narrowed, swollen, and excess mucus-producing airways, which makes breathing difficult. Salbutamol is used to treat asthma and chronic obstructive pulmonary disease (COPD.It works by relaxing the muscle of the airways into the lungs, which makes it easier to breathe . It functions by loosening the muscles in the lungs' airways, which facilitates breathing. Salbutamol is available as an inhaler, tablets, and certain liquid oral dose forms, but due to patient noncompliance issues, oral jellies containing salbutamol sulphate were developed. This study's aim is to create oral jelly, which by avoiding first pass effect, promotes patient compliance and bioavailability while avoiding many negative effects of conventional dosage forms Salbutamol sulphate oral jelly is simple to swallow and improves patient compliance in paediatric patients. Many paediatric patients find it difficult to swallow tablets and capsules, as well as to use the salbutamol inhalation in cases of asthma. The best In vitro medication release was demonstrated by the salbutamol sulphate oral jelly (F2) batch at 85% in 60 minutes. The drug concentration was discovered to be between 98.23% and 99.25%, which was within the pharmacopoeial range of 98% to 101%. Salbutamol sulphate's UV spectra were examined, and it was discovered that its greatest absorption occurs at 217.50 nm. The cost-effective salbutamol sulphate oral soft jelly also demonstrated improved compliance and an increase in bioavailability.
 Keywords: Oral Jelly, Asthma, Patient Compliance, Salbutamol Sulphate, Paediatric Patients